Calamos Advisors LLC Acquires 307,363 Shares of Precigen, Inc. $PGEN

Key Points

• Calamos Advisors opened a new Precigen position, acquiring 307,363 shares worth approximately $2.63 million, or about 0.09% of the company.
• Precigen reported quarterly earnings of $0.08 per share, beating the cited $0.06 consensus, and revenue of $74.15 million versus estimates of $71.55 million.
• Insiders sold 235,000 shares in the quarter for approximately $1.75 million; one executive’s sale was to cover tax withholding on vested equity awards.

Calamos Advisors LLC acquired a new position in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 307,363 shares of the biotechnology company's stock, valued at approximately $2,631,000. Calamos Advisors LLC owned approximately 0.09% of Precigen at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Corient Private Wealth LP bought a new stake in shares of Precigen in the 2nd quarter worth about $1,908,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Precigen during the 2nd quarter worth about $519,000. Bank of New York Mellon Corp acquired a new stake in shares of Precigen during the 2nd quarter worth about $2,705,000. Bank of America Corp DE bought a new position in Precigen during the 2nd quarter valued at about $10,536,000. Finally, Squarepoint Ops LLC lifted its holdings in Precigen by 462.8% during the 2nd quarter. Squarepoint Ops LLC now owns 353,272 shares of the biotechnology company's stock valued at $2,014,000 after purchasing an additional 290,505 shares during the last quarter. 33.51% of the stock is owned by institutional investors.

Insider Activity

In other Precigen news, COO Rutul Shah sold 34,658 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $7.50, for a total transaction of $259,935.00. Following the sale, the chief operating officer owned 465,012 shares of the company's stock, valued at $3,487,590. This represents a 6.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the sale, the director directly owned 17,100 shares in the company, valued at approximately $127,224. This represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 235,000 shares of company stock worth $1,751,400. 41.40% of the stock is owned by corporate insiders.

Precigen Price Performance

Precigen stock opened at $4.47 on Monday. The business's fifty day moving average is $6.98 and its two-hundred day moving average is $5.28. The company has a debt-to-equity ratio of 1.12, a quick ratio of 4.83 and a current ratio of 5.58. The firm has a market cap of $1.60 billion, a P/E ratio of 44.70 and a beta of 1.01. Precigen, Inc. has a 52 week low of $3.04 and a 52 week high of $8.98.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. Precigen had a return on equity of 57.93% and a net margin of 15.55%. The company had revenue of $74.15 million during the quarter, compared to analyst estimates of $71.55 million. During the same period last year, the company posted ($1.06) earnings per share. The firm's quarterly revenue was up 2437.6% compared to the same quarter last year. Equities research analysts forecast that Precigen, Inc. will post 0.27 earnings per share for the current fiscal year.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

Wall Street Analyst Weigh In

PGEN has been the topic of a number of recent analyst reports. Zacks Research lowered shares of Precigen from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 5th. Wall Street Zen raised shares of Precigen from a "buy" rating to a "strong-buy" rating in a research note on Sunday. B. Riley Financial initiated coverage on shares of Precigen in a report on Friday, September 25th. They set a "buy" rating and a $12.00 price objective for the company. Citizens Jmp lifted their target price on shares of Precigen from $11.00 to $12.00 and gave the company a "market outperform" rating in a research note on Thursday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Precigen in a research note on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $13.50.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen's pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.